No abstract

We describe the synthesis of novel triazole-incorporated diindolylmethanes (DIMs) using a molecular hybridization approach. The antitubercular activity of the DIMs against H37Ra (ATCC 25177) was tested in the active and dormant state. Among all the synthesized conjugates, the compounds ,, ,, ,, and displayed good antitubercular activity against both the active and dormant H37Ra strain. The compound exhibited good antitubercular activity against dormant H37Ra with an IC value of 1 μg mL and IC (MIC) value of 3 μg mL. The compounds ,, and displayed good antitubercular activity against active H37Ra with IC values of 2.19, 1.52, and 0.22 μg mL, respectively. The compounds ,, , and displayed more than 70% inhibition against the Gram-positive strain at 3 μg mL. The molecular docking study showed the binding modes of the titled compounds in the active site of the DprE1 enzyme and assisted with elucidating a structural basis for the inhibition of .

The efficiently designed and synthesized novel 2,4‐dimethyl‐5‐((E)‐3‐phenyl‐3‐oxoprop‐1‐enyl)‐1H‐pyrrole‐3‐carboxylic acid derivatives has been described here which is encouraged by the anticancer activities associated with sunitinib and semaxanib. Synthesized compounds were characterized by 1H NMR, 13C NMR and high‐resolution mass spectrometry (HRMS). They are evaluated for in vitro antiproliferative properties on cancer cell lines as well as antibacterial activity against gram‐positive and gram‐negative species. The bioassay results revealed that several compounds exhibit potential antiproliferation activity. Among them, the lead compound 2,2,2‐trifluoroethyl 5‐((E)‐3‐(3‐fluoro‐4‐(trifluoromethyl)phenyl)‐3‐oxoprop‐1‐enyl)‐2,4‐dimethyl‐1H‐pyrrole‐3‐carboxylate (9 g) showed the most potent anticancer activity against MDA‐MB‐231 and PC‐3 cancer cell line with GI50 values of 5.51 and 5.15 μg/mL and subsequently more active than sunitinib (GI50: 6.50 μg/mL) against PC‐3. Same compound 9 g also exhibits the most potent antibacterial activity against gram‐positive bacteria Bacillus subtilis and Staphylococcus aureus with IC50 of 1.44 and 1.54 μg/mL. In silico prediction, shows that all seven potent compounds obeyed Lipinski rule for druglikeness. Structure‐activity relationship (SAR) study reflect the activity enhance with electron withdrawing group on aryl ring and replacement of acid by its bioisosteres i. e. amide and ester group. These studies have successfully identified many newly synthesized compounds as potential anticancer as well as antibacterial agent for further development.

In the present investigation, a series of bicyclic [2-(2,4-dimethylphenylthio)phenyl] aniline analogues were synthesized and characterized by IR, NMR (1 H and 13 C) and mass spectra. All newly synthesized 15 compounds were inspected for their in vitro antitubercular activity against Mycobacterium tuberculosis (MTB) H 37 Ra in both active and dormant state using an established XTT Reduction Menadione assay (XRMA). The titled compounds exhibited minimum inhibitory concentration (MIC90) ranging from 0.05 to >30 (μg/mL). The potent four compounds were further evaluated in THP-1 infection model where they demonstrated significant antitubercular activity. All the ex vivo active were further evaluated for cytotoxic activity against THP-1, MCK-7 and HeLa cell lines in order to check selectivity index. All compounds were further screened against four different bacteria to assess their selectivity towards MTB. These derivatives could be considered as a precursor structure for further design of antituberculosis agent.